Dual Synergistic Tumor-Specific Polymeric Nanoparticles for Efficient Chemo-Immunotherapy

Area of Science:

• Oncology
• Nanomedicine
• Cancer Immunology

Background:

• Cancer treatments face challenges from cell cycle checkpoints and PD-L1 upregulation.
• Existing chemo-immunotherapies are limited by tumor self-defense mechanisms.

Purpose of the Study:

• To design norcantharidin-platinum codelivery nanoparticles (NC-NP) for synergistic chemo-immunotherapy.
• To overcome cancer's resistance mechanisms, including cell cycle arrest and PD-L1 expression.

Main Methods:

• Developed tumor-acidity-sensitive nanoparticles for controlled release of 1,2-diaminocyclohexane-platinum(II) (DACHPt) and norcantharidin (NCTD).
• Investigated NCTD's role in inhibiting protein phosphatase 2A (PP2A) and downregulating PD-L1.
• Assessed NC-NP's efficacy in vitro and in orthotopic 4T1 tumor models.

Main Results:

• NC-NP demonstrated tumor-specific release of DACHPt and NCTD in acidic tumor microenvironments.
• NCTD effectively relieved cell cycle arrest and reduced PD-L1 expression, enhancing platinum chemotherapy.
• NC-NP promoted T cell recruitment and robust antitumor immune responses, leading to significant tumor regression.

Conclusions:

• NC-NP offers a dual synergistic approach, combining chemotherapy and immunotherapy.
• This strategy effectively overcomes cancer cell defense mechanisms and enhances therapeutic outcomes.
• NC-NP represents a promising paradigm for advanced cancer treatment.